|
 |
|
Volume 3, Number 5, Supplement 2 (September/October 2005) | ||||
| ASCO 2005: Selected Abstracts on Growth Factors in Cancer Management Harold J. Burstein, MD, PhD Guest Editor |
||||
Introduction |
||||
4 |
Supportive Care for Cancer Patients: Progress and Challenges Breast Oncology Center, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts
|
|||
Anemia |
||||
6 |
Final Results of a Phase III, Randomized, Open-Label Study of Darbepoetin Alfa 200 µg Every 2 Weeks Versus Epoetin Alfa 40,000 U Weekly in Patients With Chemotherapy-Induced Anemia UCLA School of Medicine, Los Angeles, CA; Amgen Inc., Thousand Oaks, CA; and The University of Texas M. D. Anderson Cancer Center, Houston
| |||
8 |
Final Hematologic Results: Epoetin Alfa 40,000 U QW Versus Darbepoetin Alfa 200 µg Q2W in Anemic Cancer Patients Receiving Chemotherapy St. Vincent’s Comprehensive Cancer Center, New York, NY; North Mississippi Hematology and Oncology Associates, Tupelo, MS; and Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ
| |||
10 |
Evaluating the Effectiveness of Darbepoetin Alfa 300 µg Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia Georgetown University Hospital, Washington, DC; New York Medical College, Valhalla, NY; Creighton University, Omaha, NE; Pacific Shores Medical Group, Huntington Beach, CA; Charleston Cancer Center, Charleston, SC; Amgen, Inc., Thousand Oaks, CA; and Ohio State University, Columbus, OH
| |||
12 |
A Phase III Randomized Trial of Two Different Dosing Schedules of Erythropoietin in Patients With Cancer-Associated Anemia: North Central Cancer Treatment Group Study N02C2 Mayo Clinic, Rochester, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hospital Oncology Program CCOP, Toledo, OH; Carle Cancer Center CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD; Scottsdale CCOP, Scottsdale, AZ; and Geisinger Clinic and Medical Center CCOP, Danville, PA
| |||
14 |
Final Results of a Randomized, Double-Blind, Active-Controlled Trial of Darbepoetin Alfa Administered Once Every 3 Weeks for the Treatment of Anemia in Patients Receiving Multicycle Chemotherapy Hôpital De Jour D’onco-Hématologie, Charleroi, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; Szt. László Hospital, Budapest, Hungary; University of Salamanca Hospital Clinic, Salamanca, Spain; Center Fréderic Joliot, Rouen, France; and Amgen Inc., Thousand Oaks, CA
| |||
16 |
Epoetin Alfa Reduces Red Blood Cell Transfusions in High-Risk Breast Cancer Patients With Adjuvant Dose-Dense, Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide University Hospital Großhadern, Munich, Germany; University Hospital, Marburg, Germany; HSK Klinikum, Wiesbaden, Germany; University Hospital, Hannover, Germany; University Hospital, Hamburg, Germany; University Hospital, Bonn, Germany; University Hospital, Koeln, Germany; University Hospital, Dusseldorf, Germany; University Hospital, Ulm, Germany; and Staedtisches Klinikum, Frankfurt, Germany
| |||
18 |
Effectiveness of Darbepoetin Alfa 200 µg Every 2 Weeks for the Treatment of Anemia in Myelodysplastic Syndrome Tennessee Oncology, Nashville, TN; and Amgen Inc, Thousand Oaks, CA
| |||
20 |
High-Dose Recombinant Human Erythropoietin Use Is Associated With Increased Overall Survival in Patients With Multiple Myeloma Cleveland Clinic Foundation, Cleveland Clinic, OH, and Cleveland Clinic Myeloma Program, Cleveland, OH
| |||
22 |
Mild Anemia Is Associated With Greater Symptom Burden and Reduced Quality of Life in Cancer Patients The West Clinic, Memphis, TN, and Supportive Oncology Services, Memphis, TN
| |||
24 |
Efficacy of Darbepoetin Alfa in Chemotherapy-Induced Anemia in Gastrointestinal Cancers University of Michigan Cancer Center, Ann Arbor; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Amgen Inc, Thousand Oaks, CA; and Center for Oncology Research & Treatment, Dallas, TX
| |||
26 |
Are There Clinical Benefits Associated With Treatment of Mild Chemotherapy-Induced Anemia? A Systematic Review Amgen Inc, Thousand Oaks, CA; UCLA School of Medicine, Los Angeles, CA; and James P. Wilmot Cancer Center, Rochester, NY
| |||
Neutropenia |
||||
28 |
Primary Prophylaxis With 3 Weekly Pegfilgrastim and Ciprofloxacin Effectively Prevent (Febrile) Neutropenia and Infection During Neoadjuvant Chemotherapy With Docetaxel/Doxorubicin/Cyclophosphamide in Breast Cancer Patients German Breast Group, Neu-Isenburg, Germany; St. Gertrauden, Berlin, Germany; HSK, Wiesbaden, Germany; Marienkrankenhaus, Stuttgart, Germany; UFK, Kiel, Germany; UFK, Rostock, Germany; Henrietten Stift, Hanover, Germany; UFK, Tübingen, Germany; UFK, Magdeburg, Germany; UFK, Marburg, Germany; and UFK, Frankfurt, Germany
| |||
30 |
Toxicity and Health-Related Quality of Life in Node-Negative Breast Cancer Patients Receiving Adjuvant Treatment With TAC or FAC: Impact of Adding Prophylactic Growth Factors to TAC Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Clínico Universitario de Valencia, Spain; Consorci Hospitalari Parc Taulí, Sabadell, Spain; Hosp Universitario Miguel Servet, Zaragoza, Spain; Pivotal S. A., Madrid, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Instituto Oncológico de Galicia, La Coruña, Spain; Hospital General Universitario de Alicante, Spain; and Hospital General Universitario de Elche, Spain
| |||
32 |
SWOG/Intergroup 9623: A Phase III Comparison of Intensive Sequential Chemotherapy to High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women With ³ Four Involved Axillary Lymph Nodes Rocky Mountain Cancer Center, Denver, CO; Southwest Oncology Group, Seattle, WA; University of Washington, Seattle; Memorial Sloan-Kettering Cancer Center and Cancer and Leukemia Group B, New York, NY; Johns Hopkins and Eastern Cooperative Oncology Group, Baltimore, MD; Mayo Clinic and North Central Cancer Treatment Group, Rochester, MN; The University of Texas M. D. Anderson Cancer Center, Houston; and Cancer Institute Medical Group, Santa Monica, CA
| |||
34 |
AERO-B03: A Randomized Phase II Trial of Dose-Dense Docetaxel in Node-Positive Breast Cancer Hôpital Henri Mondor, APHP, Créteil, France; Institu Sainte Catherine, Avignon, France; Hôpital Départemental, La Roche Sur Yon, France; Clin Saint-Come et Saint-Damien, Blois, France; Clinique Sainter Clotilde, Saint Denis de la Reunion, France; Hôpital Fontenoy, Chartres, France, Centre Azuréen de Cancerologie, Mougins, France; Clinique de l’Espérance, Hyeres, France; CRCL Val d’Aurelle, Montpellier, France; and Centre Hospitalier, Draguignan, France
| |||
36 |
Designing Lenograstim Administration for Neutropenia Prophylaxis After Docetaxel-Epirubicin Chemotherapy Oncolgie Médicale, Pierre-Benite, France; Université de la Liberté, Marseille, France; and Université Lyon I, Lyon, France
| |||
38 |
A Risk Model for First-Cycle Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy University of Rochester, Rochester, NY; Duke University, Durham, NC; and University of Washington, Seattle, WA
| |||
40 |
Phase II Trial of R-CHOP Plus Maintenance Rituximab for Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma With Filgrastim Support for Patients Older Than 60 Years Virginia Cancer Institute, Richmond, VA; Maine Center for Cancer Medicine and Blood Disorders, Scarborough; Oncology Hematology Group of South Florida, Miami; Northwestern Carolina Oncology and Hematology, Hickory, NC; New Mexico Oncology Hematology Consultants, Albuquerque; AMF Consulting Inc., Los Angeles, CA; and Amgen Inc, Thousand Oaks, CA
| |||
42 |
A Large Study of the Older Cancer Patient in the Community Setting: Initial Report of a Randomized Controlled Trial Using Pegfilgrastim to Reduce Neutropenic Complications H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Geriatric Oncology Consortium, Baltimore, MD; Cabrini Center for Cancer Care, Alexandria, LA; Amgen Inc., Thousand Oaks, CA; and Institute for Advanced Studies in Aging, Washington, DC
| |||
44 |
Frequency of Neutropenia-Related Events During Chemotherapy and the Use of Pegfilgrastim and Filgrastim in Community Practice: Results of the ACCEPT Study Oncology Consultants, PA, Houston, TX; Private practice, Troy, MI; Pacific Cancer Medical Center, Anaheim, CA; and Amgen Inc, Thousand Oaks, CA
| |||
46 |
Impact of First and Subsequent Cycle Pegfilgrastim on Neutropenic Events in Patients Receiving Myelosuppressive Chemotherapy: Preliminary Results of FIRST, a Prospective Community-Based Study University of Oklahoma Cancer Center, Oklahoma City; Center for Oncology Research and Treatment, Dallas, TX; Hematology-Oncology of Rockland, New City, NY; and Amgen Inc., Thousand Oaks, CA
| |||
48 |
Phase II/III Trial of Induction Chemotherapy With Cisplatin/Fluorouracil (PF) vs Docetaxel Plus PF Followed by Chemoradiotherapy (CRT) vs CRT for Unresectable Locally Advanced Head and Neck Cancer Hospital 12 de Octubre, Madrid, Spain; Hospital Clínic i Provincial, Barcelona, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital General Universitario de Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital del Mar, Barcelona, Spain; and Hospital Clínico de Salamanca, Spain
| |||
50 |
Meta-Analysis of Prophylactic Granulocyte Colony-Stimulating Factor in Cancer Patients Receiving Chemotherapy University of Rochester School of Medicine and Dentistry, NY; Duke University, Durham, NC; and University of Washington, Seattle
| |||
52 |
Economic Analysis of Pegfilgrastim in Patients Receiving Cancer Chemotherapy Albany College of Pharmacy, NY; University of Rochester, NY; University of Washington, Seattle; and Duke University, Durham, NC
| |||
54 |
SWOG S0102: A Phase II Study of Docetaxel and Vinorelbine + Filgrastim for HER-2-Negative, Stage IV Breast Cancer University of Washington School of Medicine, Seattle, WA; Southwest Oncology Group, Seattle, WA; City of Hope, Duarte, CA; Puget Sound Oncology Consortium, Seattle, WA; University of Kansas, Kansas City, KS; and Scott and White Clinic, Temple, TX
| |||
56 |
Hemapoietic, Immunomodulatory, Antitumor, and Toxicity Profiles of Sequential GM-CSF and IFNg-1b Biotherapy and Carboplatin in Recurrent Ovarian Carcinoma The University of Texas M. D. Anderson Cancer Center, Houston
| |||
58 |
Final Results of a Randomized Phase III Trial of Docetaxel, Carboplatin, and Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Locally Advanced Gastric Cancer Alexandria University, Alexandria, Egypt; and Medical Research Institute, Alexandria, Egypt
| |||
59 |
The Quality Oncology Practice Initiative: Understanding and Improving Practices in a Community of Oncologists American Society of Clinical Oncology, Alexandria, VA; Oncology Hematology Care, Cincinnati, OH; Virginia Cancer Institute, Richmond, VA; University of Cincinnati College of Pharmacy, Cincinnati, OH; and Simone Consulting Co., Dunwoody, GA
| |||
Mucositis |
||||
60 |
Phase I Trial of Velafermin (CG53135-05) to Prevent Mucositis in Patients Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation New York Presbyterian Hospital, New York, NY; CuraGen Corporation, Branford, CT
| |||
62 |
Economic Implication of Outcomes Complicating Hematopoietic Stem Cell Transplant for Multiple Myeloma, Hodgkin’s Lymphoma, and Non-Hodgkin’s Lymphoma The University of Texas M. D. Anderson Cancer Center, Houston
| |||
Supported by an unrestricted educational grant from Amgen Inc. |
||||
© 2005 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
||||
58 kb